Human Genome keeps focus on Albuferon, LymphoStat-B, Abthrax

By Lisa Kerner

Charlotte, N.C., Nov. 16 - While Human Genome Sciences, Inc. has a broad pipeline of products at various stages of development, key value drivers continue to be Albuferon, LymphoStat-B and Abthrax, according to chief operating officer and chief financial officer Barry A. Labinger.

Labinger presented an overview of the company's product pipeline and key financial data at the JMP Securities Sector Focus Conference in Boston on Thursday.

The company's trial receptor program includes mid-stage development products for cancer as well as LymphoStat-B for the rheumatoid arthritis indication.

Labinger noted that in conjunction with its development partner GlaxoSmithKline plc, Human Genome is developing Relacatib for bone disease, GSK 649868 for sleep disorders, GSK 716155 for diabetes and CCRS mAB for HIV/AIDS. Human Genome has a "significant financial right" to the products, including worldwide royalties of 10% and a 20% co-promotion deal in the United States, Labinger said.

Selected financial data highlighted at the conference included Human Genome's $794.2 million of cash and 132.5 million shares outstanding on Sept 30.

The company has $280 million of convertible notes due in 2011 and $230 million of convertible notes due in 2012.

The loss for the first nine months of 2006 was $184.2 million, compared with $169.9 million for the same period of 2005.

Human Genome Sciences is a Rockville, Md., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.